Drugs / HCP1904-1
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05407220 | Jun → Jul 2022 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT05191563 | Jul → Sep 2021 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04820907 | Oct 2020 → Sep 2021 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05723549 Comparator | Feb → Mar 2023 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HCP1904-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05191563 ↗ |
| Route | Oral | “orally” NCT04820907 ↗ |